NCT05260671View on ClinicalTrials.gov

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

December 25, 2024

Study Completion Date

December 25, 2026

Conditions
Head and Neck NeoplasmsRecurrent DiseaseMetastatic Cancer
Interventions
DRUG

Penpulimab combined with cetuximab

PD-1 antibody combined with EGFR inhibitors, biweekly

Trial Locations (2)

130021

RECRUITING

Department of radiotherapy,The First Bethune Hospital of Jilin University, Changchun

Unknown

RECRUITING

Department of Radiotherapy, Eye & ENT Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Eye & ENT Hospital of Fudan University

OTHER